Specialists of the domestic pharmaceutical company Farmak have developed and brought to market a drug for the treatment of acute (stroke) and chronic cerebrovascular disorders: Lira (citicoline). The new drug is produced in the form of a solution for injection in 1000 mg ampoules No. 5 and 500 mg ampoules No. 5.
Farmak is actively working in the sphere of treatment of cardiovascular diseases. In particular, much attention is given to ensure comprehensive effective and affordable treatment of acute and chronic cerebrovascular disorders. To achieve this objective, the company’s specialists have developed and brought to market the drug product Lira (citicoline).
Lira is indicated in the acute phase of cerebrovascular disorders and for the treatment of cerebrovascular complications and sequelae; in craniocerebral traumas and their consequences, neurological disorders (cognitive, sensitive and motor) caused by degenerative and vascular cerebral disorders.
The course of treatment with the drug is 4-6 weeks.
